[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366872-105":59,"doc-detail-366872-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","from-detection-to-delay-real-world-gaps-in-post-cologuard-colonoscopy-adherence","From Detection to Delay - Real-World Gaps in Post-Cologuard® Colonoscopy Adherence","","Colorectal cancer remains a leading cause of cancer deaths, making early detection critical. Cologuard® is a non-invasive stool DNA test that detects biomarkers for CRC and precancerous lesions, but it requires follow-up colonoscopy and can yield false positives. This retrospective TriNetX analysis assessed colonoscopy follow-up within 12 months after positive Cologuard® and documented diagnostic outcomes during follow-up.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/from-detection-to-delay-real-world-gaps-in-post-cologuard-colonoscopy-adherence/366872/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/from-detection-to-delay-real-world-gaps-in-post-cologuard-colonoscopy-adherence/366872.png","ImageObject",300,407,{"name":92,"@type":93},"mieayamfan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary goal of this study?","Question",{"text":112,"@type":113},"To evaluate colonoscopy follow-up rates within 12 months after a positive Cologuard® result and examine diagnostic outcomes from that follow-up.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study conducted and who was included?",{"text":117,"@type":113},"A retrospective cohort study used the TriNetX database to analyze patients aged 18 years and older who tested positive on Cologuard®.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings about follow-up adherence and diagnoses?",{"text":121,"@type":113},"Only 44% of positive Cologuard® patients underwent follow-up colonoscopy within 12 months; among those, 5.8% had malignant neoplasms and 32.7% had benign neoplasms (polyps).",{"name":123,"@type":110,"acceptedAnswer":124},"Why do the authors emphasize patient education and care pathways?",{"text":125,"@type":113},"Low adherence and a high false-positive rate indicate missed opportunities, so improved education, streamlined care pathways, and better communication are needed to enhance follow-up compliance.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},366872,1790168050,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":133,"read_time":52,"preview_page_count":19,"preview_urls":147},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Journal of Gastrointestinal Cancer (2025) 56:224  \n[https://doi.org/10.1007/s12029-025-01350-5](https://doi.org/10.1007/s12029-025-01350-5)  \nBRIEF REPORT  \nFrom Detection to Delay: Real-World Gaps in Post-Cologuard® Colonoscopy Adherence  \nMuhammad Ali Ibrahim Kazi1 · Imran Qureshi2 · Akshay Sharma1 · Nirav Agrawal1 · Mahnoor Sarfraz3 · Barry Meisenberg1 · Sanmeet Singh1  \nAccepted: 3 November 2025 © The Author(s) 2025  \nAbstract  \nPurpose Colorectal cancer remains a leading cause of cancer deaths, highlighting the need for early detection. Cologuard®, a non-invasive stool DNA test, detects biomarkers for CRC and precancerous lesions but requires follow-up colonoscopy and has a high false-positive rate. This study evaluates colonoscopy follow-up rates and diagnostic outcomes after positive Cologuard® results.  \nMethods We conducted a retrospective cohort study using the TriNetX database, a global federated real-world data platform, to analyze patients aged ≥ 18 years who tested positive on Cologuard. The primary outcome was whether patients underwent an endoscopic procedure (colonoscopy) within 12 months of a positive result. The secondary outcome was the diagnoses made during follow-up colonoscopy, including malignant neoplasms (colorectal cancer) and benign neoplasms (polyps) . Results A total of 3,916 patients underwent Cologuard® testing, with 61 .3% being female, 35% male, and 3.7% other genders. Of the 385 patients who tested positive for Cologuard® (mean age 65 ± 8.75 years), 171 (44%) underwent follow-up colonoscopy within 12 months. Of these, 10 cases (5.8%) were diagnosed with malignant neoplasms, and 56 cases (32.7%) were diagnosed with benign neoplasms (polyps) .  \nConclusion The study found poor follow-up adherence, with only 44% completing colonoscopy and a high false positive rate with just 38 .5% of positive Cologuard® results showing significant lesions. These findings emphasize the need for better patient education, streamlined care pathways, and improved communication to enhance follow-up compliance.  \nKeywords Colorectal cancer · Cancer screening · Cologuard · Colonoscopy adherence · Care navigation  \n􀀍 Imran Qureshi [iaq5@njms.rutgers.edu](iaq5@njms.rutgers.edu)  \n􀀍 Akshay Sharma [asharma@luminishealth.org](asharma@luminishealth.org)  \n􀀍 Nirav Agrawal [nagrawal@luminishealth.org](nagrawal@luminishealth.org)  \nMuhammad Ali Ibrahim Kazi  \n[mkazi@luminishealth.org](mkazi@luminishealth.org)  \nMahnoor Sarfraz  \n[mahnoor.sarfraz@scholar.aku.edu](mahnoor.sarfraz@scholar.aku.edu)  \nBarry Meisenberg  \n[bmeisenber@luminishealth.org](bmeisenber@luminishealth.org)  \nSanmeet Singh  \n[ssingh4@luminishealth.org](ssingh4@luminishealth.org)  \n1 Anne Arundel Medical Center, Annapolis, MD, USA  \n2 Rutgers New Jersey Medical School, Newark, NJ, USA  \n3 Aga Khan University, Karachi, Pakistan  \nIntroduction  \nCologuard® is a noninvasive, at-home screening test which is prescribed to detect colorectal cancer and advanced precancerous lesions in patients who are aged 45 and older and are at risk [1] . The test functions by identifying abnormal DNA markers found to be associated with colorectal neoplasia as well as the presence of occult hemoglobin in the stool, which both serve as potential indicators of cancerous or precancerous lesions in the colon [2] . It is a test that has risen in popularity. The use of DNA stool tests for colorectal cancer screening has increased more than nine-fold since 2018, rising from 3% of screenings in the first quarter of 2018 to 31% of screenings in the fourth quarter of 2023 [3] .  \nThe Cologuard® has exhibited a high sensitivity for detecting CRC in clinical studies making it an important tool for screening and early detection. The Cologuard® test has two generations having undergone improvement in sensitivity  \n1 3  \nand specificity. The first generation demonstrated a sensitivity of 92% for colorectal cancer and 42% for precancerous lesions [1] . One study showed that the Cologuard® detected ","cbCairaTmCXkkgye","https://ap.wps.com/l/cbCairaTmCXkkgye","pdf",682854,"English","# Abstract\n# Purpose\n# Methods\n## Study design and data source\n## Outcomes\n# Results\n# Conclusion\n# Introduction\n## Cologuard® screening background and performance\n## Limitations and follow-up importance\n## Barriers and care pathway implications","[{\"question\":\"What was the primary goal of this study?\",\"answer\":\"To evaluate colonoscopy follow-up rates within 12 months after a positive Cologuard® result and examine diagnostic outcomes from that follow-up.\"},{\"question\":\"How was the study conducted and who was included?\",\"answer\":\"A retrospective cohort study used the TriNetX database to analyze patients aged 18 years and older who tested positive on Cologuard®.\"},{\"question\":\"What were the key findings about follow-up adherence and diagnoses?\",\"answer\":\"Only 44% of positive Cologuard® patients underwent follow-up colonoscopy within 12 months; among those, 5.8% had malignant neoplasms and 32.7% had benign neoplasms (polyps).\"},{\"question\":\"Why do the authors emphasize patient education and care pathways?\",\"answer\":\"Low adherence and a high false-positive rate indicate missed opportunities, so improved education, streamlined care pathways, and better communication are needed to enhance follow-up compliance.\"}]","From Detection to Delay - Real-World Gaps in Post-Cologuard® Colonoscopy Adherence | PDF",[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2f4b78dccad7d6a64b4bd7eaba5e0db.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d65003587b721e1dc89a23e1814ba1b.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87674ec7e9ae09f600e78d5cc804bad1.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b07c00e5a908cc62c02893df0532d827.webp",980,1301]